Analysts Expect Aeglea Bio Therapeutics Inc (AGLE) to Post ($0.55) Earnings Per Share
Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has received a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Brokers have set a 12 month consensus price target of $24.00 for the company and are predicting that the company will post ($0.55) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Aeglea Bio Therapeutics an industry rank of 98 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research raised Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a research report on Friday, November 10th.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.07. The business had revenue of $1.26 million for the quarter. Aeglea Bio Therapeutics had a negative return on equity of 44.05% and a negative net margin of 527.99%. equities research analysts forecast that Aeglea Bio Therapeutics will post -1.97 earnings per share for the current fiscal year.
In other Aeglea Bio Therapeutics news, CFO Charles N. York II bought 25,959 shares of the business’s stock in a transaction on Tuesday, December 5th. The shares were bought at an average cost of $4.48 per share, with a total value of $116,296.32. Following the transaction, the chief financial officer now directly owns 10,828 shares in the company, valued at approximately $48,509.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Charles N. York II bought 6,500 shares of the business’s stock in a transaction on Friday, December 1st. The stock was acquired at an average cost of $4.59 per share, for a total transaction of $29,835.00. Following the completion of the transaction, the chief financial officer now owns 10,828 shares in the company, valued at $49,700.52. The disclosure for this purchase can be found here. Insiders have purchased a total of 44,515 shares of company stock worth $204,325 over the last three months. 27.00% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of AGLE. Susquehanna International Group LLP bought a new position in Aeglea Bio Therapeutics during the 2nd quarter worth $653,000. Bank of New York Mellon Corp acquired a new stake in shares of Aeglea Bio Therapeutics in the first quarter valued at $157,000. Vanguard Group Inc. lifted its holdings in shares of Aeglea Bio Therapeutics by 9.4% in the second quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock valued at $579,000 after buying an additional 12,966 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in shares of Aeglea Bio Therapeutics in the first quarter valued at $270,000. Institutional investors and hedge funds own 46.89% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Analysts Expect Aeglea Bio Therapeutics Inc (AGLE) to Post ($0.55) Earnings Per Share” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/12/06/analysts-expect-aeglea-bio-therapeutics-inc-agle-to-post-0-55-earnings-per-share.html.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeglea Bio Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.